Insilico Medicine advances AI-discovered drug to Phase III clinical trials for idiopathic pulmonary fibrosis

Insilico Medicine advances AI-discovered drug to Phase III clinical trials for idiopathic pulmonary fibrosis

Insilico Medicine, a pioneering company in the use of artificial intelligence for drug discovery, has announced that it will advance rentosertib — a drug identified entirely by AI algorithms — to Phase III clinical trials. The therapeutic target is idiopathic pulmonary fibrosis (IPF), a devastating disease that progressively destroys lung tissue and carries a grim prognosis for patients.

This advancement is considered one of the most significant milestones in the recent history of computational medicine: for the first time, a drug generated and discovered by AI has surpassed the initial safety phases and entered the final stage of large-scale efficacy validation.

---

What is Idiopathic Pulmonary Fibrosis?

Idiopathic pulmonary fibrosis is a chronic, progressive disease that causes severe scarring of lung tissue, irreversibly compromising the patient's respiratory capacity. Its origin remains unknown — hence the term "idiopathic" — and the diagnosis is usually devastating.

• The median survival rate after diagnosis ranges between two and four years
• There is no definitive cure currently available on the market
• Existing treatments only slow the progression of the disease without reversing it
• IPF primarily affects adults over 50 years of age

Given this scenario, the urgency for new therapeutic approaches is immense, and AI is emerging as a promising tool to accelerate the discovery of innovative drug candidates.

---

The Role of Artificial Intelligence: The Pharma.AI Platform

The development of rentosertib was conducted entirely by Pharma.AI, Insilico Medicine's proprietary computational pipeline. The platform is divided into specialized engines, each responsible for a specific step in the drug discovery and development process.

PandaOmics: Biological Target Discovery

The first engine, called PandaOmics, executes the therapeutic target discovery phase. The system processes massive volumes of biological data, including:

• Genomics and proteomics
• Results from previous clinical trials
• Academic scientific literature
• Patent intelligence

Based on this data, PandaOmics builds comprehensive biological network models and applies causal inference mechanisms to identify hidden connections between molecular targets and diseases.

In the case of IPF, the system identified TNIK (TRAF2- and NCK-interacting kinase) as the primary biological target — a choice that proved innovative as it completely bypassed the receptor tyrosine kinase pathways explored by existing antifibrotic drugs.

Why is TNIK a Revolutionary Target?

PandaOmics mapped TNIK as a central node that regulates both fibrosis and inflammation through multiple signaling pathways, including:

• Wnt
• TGF-β
• Hippo/YAP-TAZ
• JNK
• NF-κB

Furthermore, the target selection process integrated an aging marker framework, scoring biological targets based on their implication in multiple mechanisms of aging, chronic inflammation, and extracellular matrix remodeling — which opens doors to a much more holistic therapeutic approach to the disease.

---

Results of Phase II Clinical Trials

The data supporting the advancement to Phase III are highly promising. A randomized clinical trial evaluated 71 patients across 22 clinical centers in China, separated into placebo and active treatment groups.

Participants received daily doses of 30 mg or 60 mg of rentosertib over an observation window of 12 weeks.

Key Results:

| Group | Change in Forced Vital Capacity (FVC) | |---|---| | Placebo | -20.3 mL (capacity loss) | | Rentosertib 60 mg/day | +98.4 mL (capacity gain) |

This difference of nearly 120 mL in forced vital capacity is clinically significant and demonstrates that the drug not only halted the progression of the disease but partially reversed the decline in lung function in treated patients.

The drug's safety profile also proved favorable, with adverse events mirroring the expected rates across all trial groups, with no alarming warning signs.

---

Regulatory Recognition: FDA Orphan Drug Designation

In February 2023, regulatory authorities in the United States — the FDA (Food and Drug Administration) — granted rentosertib Orphan Drug Designation. This status is assigned to drugs intended for the treatment of rare diseases and offers a series of incentives to the developer, including:

• Market exclusivity for seven years following approval
• Waivers of registration fees
• Accelerated regulatory assistance and guidance

This recognition reinforces both the clinical relevance of IPF and the seriousness of the therapeutic candidate developed by Insilico Medicine.

---

A Milestone for Computational Drug Discovery

The advancement of rentosertib to Phase III goes far beyond a specific product. It represents a full-scale proof of concept for the entire pharmaceutical industry regarding the transformative potential of artificial intelligence in the development of new drugs.

Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine, highlighted that IPF is one of the clearest clinical examples where AI can make a difference — a disease with urgent medical need, complex biology, and very few available therapeutic options.

What this advancement means for the sector:

• Reduction in development time: the Insilico Medicine AI pipeline identified and developed the candidate in a fraction of the conventional time
• Discovery of novel targets: the computational approach revealed a biological target that was not on the radar of traditional researchers
• Empirical validation: the Phase II clinical results provide concrete data to justify investment in AI within the pharmaceutical industry

---

The Future of AI in Medicine

Insilico Medicine's case with rentosertib is just one chapter of a larger revolution underway. Companies around the world are betting that artificial intelligence can drastically reduce the average time to develop a new drug — which currently takes between 10 and 15 years and costs billions of dollars.

The combination of multi-omics, deep neural networks, causal inference, and generative molecule models is creating a new era of pharmacology, where computers and scientists work together to unravel the complexities of human diseases at a speed never before imagined.

If the Phase III trials for rentosertib confirm the efficacy observed in earlier phases, the world may have in its hands not just a new treatment for idiopathic pulmonary fibrosis — but also the definitive validation that artificial intelligence has arrived to permanently transform drug development.

---

Source: AI News / Insilico Medicine